Atumelnant clinical trials
Also written CRN04894.
How each study uses atumelnant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the atumelnant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test atumelnant, phase 3 first.
- May 2027A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaPhase 3 · Crinetics Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses atumelnant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)RecruitingPhase 2/3Crinetics Pharmaceuticals Inc.NCT07159841Written as Atumelnant
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaRecruitingPhase 3Crinetics Pharmaceuticals Inc.NCT07144163Written as Atumelnant
- An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaRecruitingPhase 2Crinetics Pharmaceuticals Inc.NCT06712823Written as atumelnant (CRN04894)
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedPhase 1/2Crinetics Pharmaceuticals Inc.NCT05804669Written as atumelnant
- Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)CompletedPhase 2Crinetics Pharmaceuticals Inc.NCT05907291Written as atumelnant (CRN04894)
- Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsCompletedPhase 1Crinetics Pharmaceuticals Inc.NCT07570082Written as Atumelnant
- A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1Crinetics Pharmaceuticals Inc.NCT07221084Written as Atumelnant
- Single and Multiple-Ascending Dose Study of CRN04894 in Healthy VolunteersCompletedPhase 1Crinetics Pharmaceuticals Inc.NCT06048887Written as CRN04894 Oral Solution
Codes
What other systems call atumelnant · ClinicalTrials.gg INT017401
- UNII (FDA) NR57FH6U1NATUMELNANTOne source FDA
- NCI Thesaurus C200540AtumelnantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NR57FH6U1N | ATUMELNANT | One source FDA |
| NCI Thesaurus | C200540 | Atumelnant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.